A shortage listing ends. 24 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Archive — June 2026
Page 5 of 5 of this archive, newest first.
Suzhou export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Singapore declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
GIP was a failed target for thirty years. Then it was not.
What adding GIP activity does, on the current evidence, and what remains unresolved.
Steady state is not a metaphor — it is an arithmetic fact about exenatide
What the pharmacokinetic data supports about dose timing, missed doses and interruption.
The tolerability data everybody quotes and nobody reads
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
From the floor in Tianjin: 20 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the new Mexico guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What a 15% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.
Germany caps liraglutide prescribing to 10 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.